Nordic Nanovector has appointed Vivet Therapeutic’s chairman and former TiGenix’s CEO, Eduardo Bravo as its new Chief Executive Officer, the company said Monday.
Bravo brings more than 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. Since 2011, as CEO of TiGenix, a dual-listed (Euronext Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured European marketing approval of its lead asset. In January 2018, Takeda Pharmaceutical Co. Ltd announced it was acquiring TiGenix for €520 million.
Prior to joining TiGenix’ predecessor, Cellerix, in 2005, Bravo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He is currently Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD).
Bravo will take up the CEO position in Nordic Nanovector on 2 July and will be based in London, UK.